MedTrace Logo

Predictor of Clinical Response to Acthar in Myositis

NCT03414086 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-08-09

No results posted yet for this study

Summary

Comparing the clinical effects of Acthar Gel before and after treatment and compare it to patients with inactive disease.

Conditions

  • Myositis
  • Dermatomyositis
  • Polymyositis

Interventions

OTHER

Healthy Control

Ten healthy adult patients evaluating serum, PBMC's, and RNA.

OTHER

Myositis in Remission

Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Rohit Aggarwal, MD · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-06
Primary Completion
2022-07-30
Completion
2022-07-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414086 on ClinicalTrials.gov